KSHV-TK is a tyrosine kinase that disrupts focal adhesions and induces Rho-mediated cell contraction

Michael B. Gill¹*, Rachel Turner¹, Philip G. Stevenson¹ and Michael Way²

¹ Division of Virology, Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge, UK.

²Cell Motility Laboratory, London Research Institute, Cancer Research UK, 44 Lincoln’s Inn Fields, London. WC2A 3LY, UK

Running title: KSHV-TK disassembles focal adhesions

Word count: 8, 628 words, 49, 456 (characters minus spaces), 58,261 (characters with spaces)

*To whom correspondence should be addressed.

email: mbg22@cam.ac.uk
Abstract

Paradoxically, the thymidine kinase (TK) encoded by Kaposi sarcoma-associated herpesvirus (KSHV) is an extremely inefficient nucleoside kinase, when compared to TKs from related herpesviruses. We now show that KSHV-TK, in contrast to HSV1-TK, associates with the actin cytoskeleton, induces extensive cell contraction followed by membrane blebbing. These dramatic changes in cell morphology depend on the auto-phosphorylation of tyrosine 65, 85 and 120 in the N-terminus of KSHV-TK. Phosphorylation of Tyrosine 65/85 and 120 results in an interaction with Crk family proteins and the p85 regulatory subunit of PI3-Kinase respectively. The interaction with KSHV-TK leads to tyrosine phosphorylation of Crk. Auto-phosphorylation of KSHV-TK also induces a loss of FAK and paxillin from focal adhesions, resulting in activation of RhoA-ROCK signalling to myosin II and cell contraction. In the absence of FAK or paxillin, KSHV-TK has no effect on focal adhesion integrity or cell morphology. Our observations demonstrate that by acting as a tyrosine kinase KSHV-TK modulates signalling and cell morphology.

KSHV / Thymidine kinase / Cell blebbing / RhoA / Focal adhesion / Crk/PI3-Kinase
Introduction

Kaposi sarcoma-associated herpesvirus is a gammaherpesvirus that is the causative agent of several human cancers including primary effusion lymphoma (PEL), the plasmablastic variant of multicentric Castleman's disease (MCD), and Kaposi's sarcoma (KS) (Cesarman et al, 1995; Chang et al, 1994; Moore et al, 1996; Soulier et al, 1995). In pre-existing HIV infections, secondary KSHV infection induces a high incidence of Kaposi's sarcoma development, demonstrating the potent oncogenic capacity of this human virus (Martin et al, 1998). The selective inhibition of KSHV encoded enzymes that are essential for viral replication may therefore provide good therapeutic targets to limit the impact of KSHV infection and disease progression.

Herpesviruses encode a variety of enzymes that are essential for their replication, including a Thymidine kinase (TK) that overcomes a rate-limiting step during viral DNA replication in non-cycling cells by phosphorylating thymidine (Chen et al, 1979). TK-deficient Herpes virus simplex virus (HSV) is avirulent because it no longer replicates in terminally differentiated neurons (Coen et al, 1989; Efstathiou et al, 1989; Valyi-Nagy et al, 1994). Additionally, pathogenesis studies with Murid Herpesvirus-4 (MuHV-4), a close relative of KSHV, have also shown that its TK is required for lytic replication in mice (Coleman et al, 2003). The fact that MuHV-4 lacking its thymidine kinase fails to infect via the upper respiratory tract argues that the TK is required for viral replication in a cell limited for nucleotides (Gill et al, 2009). The pivotal role of these viral nucleoside kinases for in vivo replication makes them good targets for anti-viral therapeutics.

The design of acyclovir, a nucleoside analogue that is selectively phosphorylated by the thymidine kinase of HSV, and subsequently inhibits the viral DNA polymerase, is a prime example of how viral enzymes can be selectively targeted to prevent viral DNA
replication (Elion, 1982; Field & Biron, 1994; Smee et al, 1983). Additionally, the effectiveness of nucleoside analogues such as Cidofovir at reducing pathologies associated with MuHV-4 infection suggests that the TK of KSHV may represent a potential target to limit lytic replication of the virus and subsequent disease (Dal Canto et al, 2000; Gangappa et al, 2002; Neyts & De Clercq, 1998; Staskus et al, 1997).

A key point in devising anti thymidine kinase-based therapies is to understand exactly how each enzyme functions. In contrast to other herpes viruses, the TKs encoded by gamma-herpesviruses consist of a unique N-terminal domain linked to a catalytic C-terminal kinase domain (Holton & Gentry, 1996; Littler & Arrand, 1988; Littler et al, 1986). They are also very inefficient thymidine kinases (Gustafson et al, 1998; Gustafson et al, 2000). For example, the thymidine kinase of KSHV has a ~ 60 fold higher Km for thymidine than that of HSV1 (Gustafson et al, 2000). Of those studied to date, the TKs encoded by gamma-herpesviruses, unlike that of HSV1, are also not found in the nucleus (Degreve et al, 1998; Gill et al, 2007; Gill et al, 2005). Gamma2 herpesvirus TKs, such as those encoded by KSHV, rhesus monkey rhadinovirus, herpes saimiri and MuHV-4, are also phosphorylated on tyrosine residues in their N-terminal domain (Gill et al, 2005). Tyrosine phosphorylation of other viral TKs has not been observed (Gill et al, 2005). KSHV, unlike MuHV-4 and EBV, also encodes a thymidylate synthetase that can generate thymidine 5’-monophosphate via an alternative route independent of TK (Gaspar et al, 2002). The TK encoded by KSHV may therefore possess other functions that can be more effectively used by the virus during replication. Such a precedent has been reported for a number of nucleoside metabolism enzymes captured by viruses that have acquired new cellular functions (Davison & Stow, 2005; Gaspar et al, 2008; Lembo et al, 2004).
Previous observations suggest that KSHV TK, which associates with unknown structures throughout the cytoplasm is capable of inducing cell rounding (Gill et al, 2005). In this study we set out to address how this viral thymidine kinase induces such morphological changes. We find that KSHV-TK is a tyrosine kinase that when auto-phosphorylated disrupts the integrity of focal adhesions and induces activation of Rho-ROCK-Myosin II dependent cell contraction and blebbing. Moreover, our results suggest that KSHV TK is a potential target for the development of tyrosine kinase inhibitors to limit its impact upon cell signalling pathways during lytic replication, to contribute to the treatment of virus-induced pathologies such as Kaposi sarcoma.

Results

KSHV-TK induces cell contraction and blebbing

Previous work reveals that KSHV-TK induces cell rounding and detachment of adherent cells (Gill et al, 2005). To obtain additional insights into these morphological changes we analyzed the effects of expressing GFP-tagged KSHV-TK (GFP-KSHV-TK) on cell morphology using time-lapse microscopy. Cells expressing GFP-KSHV-TK initially had a flat epithelial morphology but were observed to undergo a dramatic contraction ~ 16 hours post-transfection (Figure 1A; Movies S1 and S2). Expression of GFP-KSHV-TK in COS-7 and BHK-21 cells resulted in a similar phenotype (Figure S1A). In contrast, expression of GFP-tagged HSV1-TK had no effect on cell shape or obvious changes in focal adhesion integrity as discussed later (Figure S1B).

Closer examination reveals that GFP-KSHV-TK expressing cells that had contracted underwent extensive membrane blebbing (Figure 1B; Movie S3). The morphological changes observed in time-lapse studies were also evident in the scanning electron microscope (Figure 1C). GFP-KSHV-TK induced membrane blebbing was not due to
apoptosis as cells remained viable as they excluded trypan blue. They also showed none of the hallmarks of apoptosis when examined in the transmission electron microscope (Figure S1C). Consistent with this, the apoptosis inhibitor Z-ZAD-FMK did not prevent GFP-KSHV-TK induced cell contraction (Figure S1D).

**KSHV-TK induced contraction is dependent on RhoA, ROCK and Myosin II**

Prior to cell contraction GFP-KSHV-TK forms an extensive array of filaments, a proportion of which align with a subset of actin stress fibres (Figure 1D). It was also noticeable that GFP-KSHV-TK also promoted an increase in the number of central actin stress fibres in spread cells before they contracted (Figures 1D and S1E). To examine how KSHV-TK induces actin stress fibre formation, we examined the consequences of inhibiting RhoA signalling via ROCK to myosin II, the major signalling pathway involved in their formation (Pellegrin & Mellor, 2007). We found that co-expression of the dominant negative GFP-RhoN19 mutant partially inhibited the ability of RFP-KSHV-TK to promote cell contraction (Figure 2A). Treatment of cells with Y-27632 or Blebbistatin, which inhibit ROCK and myosin II respectively, also abrogated KSHV-TK induced stress fibre formation and cell contraction (Figure 2B). Treatment of cells with Y-27632 or Blebbistatin, in the absence of KSHV-TK, did not alter the integrity of focal adhesions (Figure S2A). Consistent, with these observations we found that the level of GTP-bound RhoA is higher in GFP-KSHV-TK expressing cells (Figure 2C).

**KSHV-TK disassembles focal adhesions**

The dramatic changes in morphology induced by KSHV-TK are indicative of a possible alteration in the interaction of the cell with the extracellular substrate. To explore this possibility, we examine whether KSHV-TK induces changes in the composition and/or integrity of focal adhesions. We found that there was a reduction in the normal
phosphotyrosine staining of focal adhesions in cells expressing GFP-KSHV-TK (Figure 2D). The reduction in phoshotyrosine signal at focal adhesions, however, was not always readily apparent as it was frequently masked by a strong phoshotyrosine signal associated with KSHV-TK (Figure 2D). To overcome this problem, we used phospho specific antibodies to examine the level of tyrosine phosphorylated FAK and paxillin at focal adhesions in cells expressing KSHV-TK (Figures 2D and S2B). Immunofluorescence analysis with antibodies against phosphorylated tyrosine 397, 861 and 925 of FAK reveals that level of activated phospho-FAK associated with focal adhesions is lower in cells expressing GFP-KSHV-TK (Figures 2D and S2B). A similar reduction in the level of phospho-paxillin was observed using antibodies directed at phosphorylated tyrosine 31 and 118 of paxillin (Figures 2D and S2B). Quantification reveals that in cells expressing GFP-KSHV-TK the phospho-Paxillin-Y31 and phospho-FAK-Y925 signal associated with focal adhesions was reduced by 84.4% and 67.23% respectively compared to GFP alone (Figure S2C). Consistent, with its inability to induce cell contraction, expression of GFP-HSV1-TK did not induce a loss in the phosphotyrosine or phospho-paxillin signal at focal adhesions or stimulate actin stress fibre formation (Figure S1).

Not only did KSHV-TK induce the loss of the phospho FAK and paxillin signal associated with focal adhesions it also altered the cellular distribution of total FAK and paxillin (Figure S3A). Staining for other focal adhesion components including Parvin, VASP, Vinculin and Zyxin revealed a similar reduction at focal adhesions together with an increase in the cytoplasmic level of the protein (Figures S3A, B). The ability of KSHV-TK to induce loss of focal adhesion integrity was identical regardless of whether the protein was tagged with GFP, RFP or not (Figure S3C).
Virally expressed KSHV-TK also induces disassembly of focal adhesions

To confirm our observations in transfected cells we sought to analyse the effect of KSHV-TK expression on focal adhesion integrity during lytic viral replication. As it is still not possible to assess the role of specific KSHV encoded proteins during lytic replication using the KSHV BAC mutagenesis system, we generated a recombinant MuHV-4 virus in which KSHV-TK was substituted for the TK of this closely related gamma herpesvirus (Figure 3A). This is possible as the MuHV-4 TK is essential for in vivo replication, but is dispensable for replication in cell culture (Coleman et al, 2003). The resulting recombinant virus is denoted MuHV-4 [g-KSHV-TK] (Figure 3A). Cells infected with MuHV-4 [g-KSHV-TK] expressed GFP-KSHV-TK, which became tyrosine phosphorylated (Figure 3B). The recombinant virus also had similar early and late lytic protein expression as the parental MuHV-4 (Figure S4A). Infection with MuHV-4 [g-KSHV-TK] induced a similar loss of the phospho-FAK Y925 and phospho-Paxillin Y31 signal associated with focal adhesions as observed in cells expressing GFP-KSHV-TK (Figure 3C). In contrast, infection with MuHV-4 had no affect on focal adhesion integrity or distribution of phospho-FAK or phospho-Paxillin (Figure 3C). The cell rounding observed in cells infected with the recombinant MuHV-4 (MuHV-4, g-KSHV-TK), expressing KSHV-TK, could be blocked by the inclusion of the ROCK inhibitor Y-27632 during viral replication (Figure 3D).

In addition, although lytic replication is very inefficient in culture we took advantage of two available systems to examine the impact of lytic KSHV replication on cell morphology. In one approach, Vero cells containing latent KSHV (rKSHV.219) (GFP+ cells) were induced to promote lytic replication, which can be observed by the expression of RFP that is driven by a pan-lytic KSHV promoter (Vieira & O'Hearn, 2004). Cells in which lytic replication was visible (GFP+/RFP+) were clearly contracted,
compared to cells with latent virus (GFP+) which retained a more flattened morphology (Figure 3E). The cell rounding observed during KSHV lytic replication could also be blocked by the incubation of Y-27632 (Figure 3E). In the second experimental approach virus was generated from a recombinant KSHV-Lyt virus that constitutively expresses the main lytic switch regulator, RTA (Budt et al, 2011). Filtered supernatants containing KSHV-lyt were then used to infect HeLa cells in the absence or presence of Y-27632. In the absence of Y-27632, infected cells (GFP+) underwent cell contraction and had a strong phosphotyrosine staining (Figure S4B). In the presence of Y-27632 the infected cells maintained a more flattened morphology (Figure S4B). Taken together our data clearly show that the ROCK specific inhibitor Y-27632 is sufficient to block the cell rounding induced by KSHV-TK in over expression and viral contexts, including KSHV lytic replication.

**Cell contraction is dependent on auto-phosphorylation of KSHV-TK**

Immunofluorescence and western blot analysis reveals that KSHV-TK is clearly tyrosine phosphorylated (Figures 2D and 3A). To examine if the catalytic activity of KSHV-TK is responsible for its auto-phosphorylation and whether this modification is required to induce cell contraction, we generated a kinase dead mutant (KSHV-TK-DEAD) by changing three essential glycine residues in the ATP binding motif of the kinase domain to Alanine (Saraste et al, 1990). Immunoblot analysis reveals that KSHV-TK-DEAD has a dramatic reduction in its level of tyrosine phosphorylation (Figure 4A). Moreover, in contrast to the wild type protein, KSHV-TK-DEAD is diffuse in the cytoplasm and does not form a reticular network, nor does it induce cell contraction or blebbing (Figures 4A, B). Immunofluorescence analysis of the distribution of FAK, Parvin, Paxillin, VASP, Vinculin and Zyxin also indicated there were no obvious changes in the integrity of focal adhesions (compare Figures 4C, 4D and S5 with Figures 2D, S2B and S3A).
To further validate the ability of KSHV-TK to act as a tyrosine kinase and auto-phosphorylate itself, we expressed and purified the protein from E. coli. The EBV and MuHV-4 related gammaherpes TKs were used as controls. Immunoblot analysis reveals that in contrast to the TKs from EBV and MuHV-4, KSHV-TK is tyrosine phosphorylated when purified from E. coli (Figure 4E). The ability of purified recombinant KSHV-TK to undergo auto-phosphorylation in the presence of ATP after treatment with protein tyrosine phosphatase 1B (PTP1B) further confirmed its tyrosine kinase activity (Figure 4E). Furthermore, the auto-phosphorylation of KSHV-TK was abolished when the kinase dead mutant was purified from E. coli (Figure 4F). By expressing the individual domains of KSHV-TK in mammalian cells, we could also demonstrate that the N-terminal region of KSHV-TK is only phosphorylated when attached to its C-terminal kinase domain (Figure 4G).

To investigate whether the loss of focal adhesion integrity is due to phosphorylation of KSHV-TK or phosphorylation of cellular targets, we set out to define which tyrosine residues are auto-phosphorylated in KSHV-TK. Western blot analysis of a series of N-terminal deletion mutants reveals that auto-phosphorylation of KSHV-TK is lost when the first 100 amino acids of this protein are removed (Figure 5A). Motif searches in the first 100 amino acids with the Scansite server (scansite.mit.edu/motifscan_seq.phtml) predict that when phosphorylated, tyrosine residues 65 and 85 of KSHV-TK are potential SH2 binding sites for a number of proteins. Given, this we mutated each tyrosine residue to phenylalanine, alone or in combination to examine their contribution to KSHV-TK induced focal adhesion disassembly. Western blot analysis reveals that the single tyrosine mutants (Y65F, and Y85F) are still phosphorylated (Figure S6A). The single mutants also induced loss of focal adhesion integrity and cell rounding that was
indistinguishable from the wild type protein (Figure S6B). In contrast, the double mutant (denoted as Y2F) had significantly reduced auto-phosphorylation and did not induce cell rounding or changes in focal adhesion integrity (Figure S6B, C). These results suggest that auto-phosphorylation of tyrosine 65 and 85 of KSHV-TK is sufficient to disrupt focal adhesion integrity and induce cell contraction. To confirm that KSHV-TK auto-phosphorylates tyrosine 65 and 85 we performed Mass spec analysis of KSHV-TK purified from E. coli. (Figure S7). This analysis confirmed tyrosine 65 and 85 are phosphorylated and also revealed that tyrosine 120 is additionally modified (Figure S7). Phosphorylation of tyrosine Y120 of KSHV-TK is also consistent with the partial phosphorylation of the Y2F mutant (Figures 5B and S6A). Mutation of tyrosine 120 in conjugation with Y65 and Y85 completely abolished tyrosine phosphorylation of KSHV-TK (Figure 5B). Cells expressing the triple mutant Y65/85/120F (denoted as Y3F) were indistinguishable from controls as they had a flat morphology and prominent focal adhesions (Figure 5C-E). Consistent with this, the KSHV-TK DEAD, Y2F and Y3F mutants failed to increase the level of GTP bound RhoA induced by the wild type protein (Figure 5F). In order to examine the impact of expressing the KSHV-TK-Y3F during lytic viral replication we generated a recombinant MuHV-4 virus. In contrast to the cell rounding induced by KSHV-TK, the MuHV-4 infected cells expressing KSHV-TK-Y3F retained a flat morphology (Figure 5G).

The kinase activity of KSHV-TK is required for its association with FAK

Expression of KSHV-TK leads to a loss of phospho-paxillin at focal adhesions (Figure 2D). Phosphorylation of paxillin at focal adhesions is mediated by a complex of FAK-Src (Frame, 2004; Glenney & Zokas, 1989; Schaller & Parsons, 1995; Schlaepfer & Mitra, 2004). It is possible that the KSHV-TK kinase activity disrupts the ability FAK-Src to phosphorylate paxillin. Consistent with this, the ability of KSHV-TK to associate with FAK
was dependent upon its kinase activity, as the KSHV-TK-DEAD but not the Y2F or Y3F mutants failed to associate with FAK (Figure 6A). To further define the contribution of FAK and paxillin in the KSHV-TK induced phenotypes, we examined the effects of expressing GFP-KSHV-TK on the localization of paxillin and zyxin in FAK<sup>−/−</sup> or paxillin depleted cells. In FAK<sup>−/−</sup> but not FAK<sup>+/+</sup> cells, both paxillin and zyxin were readily detected in peripheral focal adhesions and the cells did not undergo contraction (Figures 6B and S6D). Immunofluorescence analysis reveals that RNAi mediated depletion of paxillin did not inhibit tyrosine phosphorylation of GFP-KSHV-TK, which still forms an extensive array of filaments throughout the cell (Figure 6C). The loss of paxillin, however, did prevent GFP-KSHV-TK induced disassembly of focal adhesions and cell contraction (Figure 6C). Our observations clearly demonstrate that KSHV-TK mediated focal adhesion disassembly and cell contraction involves FAK and paxillin.

**KSHV-TK interacts with Crk family members and the p85 subunit of PI3-kinase**

We set out to identify cellular binding partners for phosphorylated tyrosine 65 and 85 given their absolute requirement in KSHV-TK induced cell contraction. Upon closer examination we realised that Y65 (pYDVP) and Y85 (pYATP) matched the preferred Crk SH2 binding motif of pY-x-x-P (Figure 7A) reviewed in (Birge et al, 2009). Immunoprecipitation of GFP-KSHV-TK and its Y2F mutant reveals that endogeneous CrkI, CrkII and CrkL interact with the wildtype protein but not with the Y2F mutant lacking tyrosines 65 and 85 (Figure 7B). Immunofluorescence analysis, also reveals that endogeneous CrkII associates with KSHV-TK but not the Y2F mutant (Figure 7C). To confirm KSHV-TK interacts with the SH2 domain of CrkL and CrkII we performed pull down assays on cells co-expressing different GFP-tagged CrkL and CrkII domains. We found that RFP-KSHV-TK only interacts with the SH2 domain of CrkL and CrkII (Figure
7D). In addition, the co-expression of either the SH2 of CrkII or CrkL was sufficient to block RFP-KSHV-TK induced cell rounding (Figure 7E).

Interestingly, tyrosine 120 of KSHV-TK conforms to the preferred PI3-Kinase SH2 binding motif of pY-x-x-M (Figure 8A)(Songyang et al, 1993). Immunoblot analysis of GFP immunoprecipitations reveals that in contrast to the wild type protein and the Y2F mutant, KSHV-TK-Y120F has a significantly reduced interaction with endogeneous p85 regulatory subunit of PI3K (Figure 8B). Furthermore, immunoprecipitations demonstrate that CrkII and/or CrkL are unable to interact with KSHV-TK via an association with PI3K (Figure 8C, D). This suggests that the two pathways downstream of phosphorylated tyrosine 65/85 and 120 are operating independently from each other.

**KSHV-TK induces phosphorylation of Crk bound to tyrosines 65 and 85**

Given that tyrosine phosphorylation of Crk family proteins impacts on their cellular function (reviewed in (Birge et al, 2009), we decided to see if KSHV-TK induces phosphorylation of CrkII and CrkL on tyrosine 221 and 207 respectively (Figure 7D). Immunoblot analysis with phospho-specific antibodies on endogeneous CrkII and CrkL immunoprecipitated from cells expressing GFP-KSHV-TK reveals that both proteins become phosphorylated in the presence of the viral kinase (Figure 8E). Increased tyrosine phosphorylation of CrkII and CrkL was not observed in cells expressing the GFP-KSHV-TK Y2F or Y3F mutants (Figure 8E). This suggests that the interaction of CrkII and CrkL with Tyrosine 65/85 of KSHV-TK is required for their phosphorylation. The Y2F result also provides further evidence that the two signalling pathways act independently, as the presence of PI3K bound to KSHV-TK does not enhance CrkII or CrkL phosphorylation. To confirm this is the case, we examined the ability of recombinant His-CrkII to bind and be phosphorylated by GFP-KSHV-TK. We found that
the wild type but not the Y2F or Y3F mutants could bind and phosphorylate His-CrkII (Figure 8F). Furthermore, the interaction of His-CrkII is specific for phosphorylated tyrosine 65/85 as in the presence of phosphorylated tyrosine 120 in the Y2F mutant there was still no binding (Figure 8F). Taken together our results indicate that Crk family members and PI3K are acting independently of each other downstream of phosphotyrosine 65/85 and 120 respectively.

Discussion

One of the most successful anti-viral therapeutics used to limit herpesvirus replication, has been the design of inhibitory nucleoside analogues, such as acyclovir and gancyclovir, that are specifically phosphorylated by the virus encoded thymidine kinase and block viral DNA replication (Elion, 1982; Elion, 1993; Galarraga et al, 2005; Reardon & Spector, 1989; Sia & Patel, 2000; Smee et al, 1985). Based on the conservation of their kinase domains one would assume that the TK expressed by the gammaherpesvirus KSHV would represent a favourable target for nucleoside analogue directed therapies. However, previous studies have shown that the thymidine kinase encoded by KSHV is an extremely inefficient enzyme compared to related herpesvirus TKs (Gustafson et al, 2000). Moreover, the ability of the TK from KSHV but not that of HSV1, to induce cell rounding when expressed in mammalian cells suggested that the two kinases may have very different functions during infection (Gill et al, 2005). In trying to understand how KSHV-TK induces cell contraction, we have now uncovered that the protein is actually a tyrosine kinase that auto-phosphorylates tyrosine 65, 85 and 120 in its N-terminal domain. Phosphorylation of tyrosines 65 and 85 of KSHV-TK ultimately leads to the loss of focal adhesion integrity and the induction of cell contraction followed by blebbing. These KSHV-TK induced morphological changes are dependent on FAK and paxillin as well as the activity of RhoA-ROCK signalling to myosin II.
It is well established that Paxillin is a pivotal player in the formation of focal adhesions (Turner, 2000). Once recruited to the leading edge of migrating cells, paxillin becomes tyrosine phosphorylated by a complex of FAK-SRC and acts as a scaffolding protein to recruit both structural and signalling proteins to the developing focal adhesion (Burridge et al., 1992; Laukaitis et al., 2001; Nakamura et al., 2000; Nikolopoulos & Turner, 2000). In this study we have demonstrated that KSHV-TK leads to a loss of paxillin phosphorylated on tyrosines 31 and 118 at focal adhesions. This presumably results from the ability of catalytically active KSHV-TK to bind to and interfere with the normal cellular functionality of FAK-SRC. When phosphorylated tyrosines 31 and 118 of paxillin bind directly to the SH2 domain of p120RasGAP preventing its interaction with p190RhoGAP, which in turn leads to the suppression of RhoA signalling at focal adhesions (Iwasaki et al., 2002; Tsubouchi et al., 2002). Our observations suggest that KSHV-TK induces cell contraction and blebbing by indirectly activating RhoA signalling to Myosin II by disrupting the ability of FAK-Src to phosphorylate tyrosine residues 31 and 118. Consistent with this, FAK deficient cells expressing KSHV-TK do not undergo contraction and focal adhesion disassembly. However, the ability of FAK to still interact with the phosphorylation deficient Y3F KSHV-TK mutant, suggests an additional cellular protein(s), presumably upstream of FAK or in addition to FAK, that enables KSHV-TK to induce focal adhesion disassembly and cell contraction.

We have now found that when phosphorylated tyrosine 65 and 85 of KSHV-TK interact with the SH2 domain of Crk family proteins. Crk family members are potent oncogenic SH2/SH3 adaptor proteins that play a critical role in regulating cell adhesion through the formation of a diverse array of signalling complexes (Birge et al., 2009). Crk family members bind to phosphorylated paxillin and p130Cas via their SH2 domain, and in
doing so partially protect these proteins from dephosphorylation by cellular phosphatases (Iwasaki et al., 2002; Schaller & Parsons, 1995; Takino et al., 2003). In the case of paxillin, phosphorylation of Y31 and Y118 is sufficient to prevent RhoA activation (Tsubouchi et al., 2002). Crk family members also bind to Rho-GTPase exchange factors DOCK180, SOS1 and C3G via their N-terminal SH3 domain (Birge et al., 2009). The formation of Cas-Crk-C3G complex promotes cell adhesion and spreading resulting from Rap1 activation (Sakakibara et al., 2002). In contrast, Paxillin-Crk-DOCK180 and Paxillin-CrkII-GIT2/PKL-β-PIX complexes promote Rac1 activation and cell spreading (Ichiba et al., 1999; Lamorte et al., 2003; Valles et al., 2004). The strong association of CrkII with KSHV-TK filaments suggests that the viral kinase is sequestering Crk family proteins away from their normal cellular binding partners including phosphorylated Paxillin. The sequestering activity immediately suggests KSHV-TK induces activation of RhoA and cell contraction by blocking the formation of Crk signalling complexes involved in promoting or maintaining cell spreading. In addition, KSHV-TK also increased the phosphorylation of CrkII and CrkL on tyrosine residues 221 and 207 respectively, a modification that promotes an auto-inhibited conformation for both proteins (reviewed in (Birge et al., 2009)). In its auto-inhibited state, the Crk N-terminal SH3 domain is also unable to interact with GEFs including DOCK180 and C3G. Failure of C3G to bind Crk inactivates Rap1 and consequently stimulates RhoA activation (Huang et al., 2008), a state reminiscent of that induced by KSHV-TK.

When phosphorylated tyrosine 120 of KSHV-TK binds to the p85 regulatory subunit of PI3-Kinase, although the biological significance of this interaction remains to be defined. Intriguingly, we do not see any association between Crk family members and the p85 subunit of PI3-K in the absence of KSHV-TK expression. The ability of phosphorylated KSHV-TK to form a complex with both Crk and pI3-K p85 is reminiscent of that observed
when tyrosine phosphorylated Cbl forms a complex with both Crk and PI3-K p85 in activated T cells (Gelkop et al, 2001). In activated T lymphocytes C3G is believed displaced from the Crk-Cbl-C3G complex enabling the formation of the Crk-Cbl-PI3-K p85 complex (Gelkop et al, 2001). C3G is known to activate Rap1, block Ras-dependent signalling, and in doing so promote immune cell anergy (Boussiotis et al, 1997; Moodie et al, 1993). The ability of KSHV-TK to simultaneously bind to both Crk and PI3-K p85 could also block C3G binding to Crk and represent a platform for further Crk and PI3-K p85 signalling.

Unfortunately, in the absence of an animal model, it is currently not possible to examine the cellular consequences of KSHV-TK expression in vivo or its contribution to KSHV pathogenesis. We have found that expression of KSHV-TK alone or in the context of infection with a recombinant MuHV-4 induces cell contraction and persistent blebbing. Lytically replicating KSHV was also capable of promoting ROCK dependent cell rounding. However understanding the precise contribution of KSHV-TK phosphorylation to viral replication and spread will only be possible once a better lytic KSHV replication system is available that permits the generation of site specific mutants, which at present are currently unavailable.

In recent years, it has become clear that cell blebbing is an important aspect driving the migration of embryonic and tumour cells in 3D environments (Charras & Paluch, 2008; Fackler & Grosse, 2008; Lammermann & Sixt, 2009; Paluch & Raz, 2013; Sahai & Marshall, 2003). As in the case of KSHV-TK, these cellular blebs are induced via the activation of RhoA-ROCK signalling to Myosin II. Bleb induced matrix deformation followed by reattachment enables cancer cells to move in an amoeboid-like fashion through the extra-cellular matrix without the requirement for proteases (Pinner & Sahai,
Based on our observations, we suggest that expression of KSHV-TK early during lytic replication will induce changes in the interaction of infected cells with both their non-infected neighbours and the extracellular matrix. It is also possible that KSHV-TK promotes infected cell migration in a manner analogous to that observed for tumour cells potentially by modulating the functionality of Crk family members and/or FAK-Src signalling via paxillin. Inducing migration of infected cells may provide a selective advantage during viral pathogenesis, as it will enhance the spread of infection independently of virus shedding. Moreover, endothelial cells, which are believed to be the source of Kaposi’s sarcoma spindle cells (Hong et al, 2004) are also capable of moving via cell blebbing (Norman et al, 2010). It is possible that TK mediated activation of RhoA during lytic virus replication, potentially via paxillin dephosphorylation and Crk phosphorylation, promotes the movement of these cells. The latter would assist in seeding KSHV infected cells to new anatomical sites for establishment and replication, consistent with the multi focal vascular nature of Kaposi’s sarcoma. The use of RhoA activation to promote cell movement contrasts the situation for vaccinia virus, where the viral protein F11 enhances the spread of infection by inducing cell migration and modulating the integrity of the cortical actin by binding RhoA to inhibit its downstream signalling (Arakawa et al, 2007a; Arakawa et al, 2007b; Cordeiro et al, 2009; Handa et al, 2013; Valderrama et al, 2006).

It is currently unclear how KSHV-TK autophosphorylates itself since its lacks a classical tyrosine kinase signature. Unfortunately, no structure of either the catalytic domain or a full-length gammaherpesvirus TK has been determined. The structure of KSHV-TK or its kinase domain will undoubtedly provide important mechanistic insights into how this viral nucleoside kinase acts as a protein tyrosine kinase. It will also help facilitate the rational design of drugs to inhibit this viral kinase that has generally been overlooked but which
should now be added to the list of potent signalling proteins expressed by KSHV. It will now be important to analyse the impact of KSHV-TK in vivo in order to assess its true oncogenic capacity and identify specific inhibitors that block the cellular effects of this viral kinase. In summary our analysis suggest that KSHV-TK represents a new potential drug target for with which to potentially limit the dissemination of lytically replicating cells infected with KSHV.

**Materials and methods**

**Expression Plasmid**

KSHV TK (ORF21) was amplified and cloned into pEGFPC2 (Clontech), pCherryC2 (a generous gift of Dr. C. Crump, Cambridge, UK) or pcDNA3.1 (-) (Invitrogen). The pEGFPC2 (or pCherryC2)-KSHV TK-DEAD were generated by PCR-based mutagenesis using the following primers 5’gccttacttaggcccgttaatggctggtgccccataacgctgtaac3’ and 5’gttgaccagcggtaatggctggtgccccataacgctgtaac3’, which change glycines 260, 263 and 265 to alanine residues in the ATP binding site. The KSHV-TK Tyrosine to Phenyalalanine mutants were generated using the following primers using site directed mutagenesis: Y65F (5’gtaaaaacctgtcattttgacgctgccccagccgtcag3’) and (5’tcgggacggtgccccagccgtcag3’), Y85F (5’tgcacgccaacctctttgcgtagggttttgcg3’) and (5’ggcggaaacctggtgggtgccccagccgtcag3’), Y120F (5’tgacgacgactggggacctttggtacgctgtaac3’) and (5’gaagcggatccattttggtgccccagccgtcag3’). The pEGFPC2 KSHV-TK N-terminal truncation clones were generated as previously (Gill et al, 2005).

Full length FAK was amplified cloned into pEGFPC2 to generate pEGFPC2-FAK. Paxillin was amplified cloned into pEGFPN2 to generate pEGFPN2-Paxillin. ORFs
encoding EBV-TK, MuHV-4-TK and KSHV-TK (and KSHV-TK-DEAD) were cloned into pGEX4T1 (Invitrogen) in frame and downstream of GST. CrkII and CrkL and subdomains (SH2, nSH3, cSH3, plus linker region+cSH3 for CrkL) were amplified cloned into pEGFPC2.

Cell lines and drugs
HeLa, COS-7, BHK, hTERT-RPE1, FAK+/ and FAK−/− (Ilic et al, 1995) cells and the cre-transduced derivative 3T3-CRE (Stevenson et al, 2002) were grown in Dulbecco's modified Eagle medium (In Vitrogen Corporation) supplemented with 2 mM glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin and 10% fetal calf serum (PAA Laboratories, Linz, Austria). For FAK+/+ and FAK−/− cells media was also supplemented with non-essential amino acids (PAA) and 50 µM 2-Mercaptoethanol (GIBCO). Cells were treated with 20 µM Y-27652 (Calbiochem), 10 µM Blebbistatin (Sigma) or 20 µM Z-VAD-FMK (Promega) 1 h post-transfection and maintained through the transfection in freshly added media.

siRNA treatments
HeLa cells were plated at 5x10⁴ cells per well and were transfected with 100 nM total siRNA in OptiMEM (Invitrogen) using Dharmafect 1 (Thermo Scientific) according to manufacturer's instructions. Both a Paxillin siRNA pool (catalogue no. 1027416 (Qiagen) or mock siRNA (sense AUUCUAUCACUAGCGUGACUU/antisense GUCACGUAGUGUAAGAAUUU) (Thermo Scientific) were used to transfct HeLa cells. Thirty hours after siRNA addition the cells were transfected with the pEGFPC2-KSHV TK using TransIT-LT1 in accordance with the manufacturers instructions (Mirus). Eighteen hours later the cells were either harvested to generate cell lysates, or fixed
using 4%PFA for immunofluorescence. Cell lysates were generated as stated below and
analysed by SDS-PAGE and immuno-blotting (as described below).

**RhoA GTP pull down assays**

1x10^7 HeLa cells were transfected with GFP, GFP-KSHV-TK, GFP-KSHV-TK mutants
(DEAD or Y6585F), or mock challenged using Lipofectamine in accordance with the
manufacturers instructions (Invitrogen). Cell lysates were generated 12 hours after the
initial transfection in 1ml using 1X MLB buffer. 500μl cell lysate was added to 23.1μl
The mixture was incubated for 45 min at 4°C with gentle agitation. The agarose beads
were pelleted (10 sec, 14, 000xg, 4°C). The beads were washed 3X with MLB and then
resuspended in 40μl of 2X laemmli reducing buffer, plus 2μl of dithiothreitol and boiled
for 5 minutes. The precipitated material was analysed by western blot analysis for
bound RhoA using RhoA using mAb sc-418 (Santa Cruz) (as described below). Input
lysates were included as a control.

**Electron microscopy**

HeLa cells expressing GFP, GFP-KSHV-TK or GFP-KSHV-TK-DEAD were processed
for both transmission and scanning electron microscopy as previously described (Bruce
et al, 2010). All samples were prepared and processed by the University of Cambridge
Multi-Imaging Centre.

**Immunofluorescence and antibodies**

HeLa, BHK-21 or COS cells grown on glass coverslips were transfected using
Lipofectamine™-2000 in accordance with the manufacturers instructions or infected with
0.5 or 1 p.f.u. / cell of MuHV-4 (wild type), MuHV-4 TK, MuHV-4 TK Revertant (Coleman et al, 2003) or MuHV-4 [g-KSHV-TK]. 16-18 post-transfection/infection cells were fixed (4% paraformaldehyde, 20 min), permeabilised (0.1% Triton X-100/PBS, 15 min) and blocked (3% bovine serum albumin in PBS/0.1% Tween [T-PBS], 1h). Primary antibodies were incubated in 3%BSA/T-PBS for 1h. The following primary antibodies were used: Phospho-tyrosine (PY99, sc-7020, Santa Cruz), Phospho-FAK Y397 (ab4803, Abcam), Phospho-FAK Y861 (ab4804, Abcam), Phospho-FAK Y925 (ab38512, Abcam), Phospho-Paxillin Y31 (ab4832, Abcam), Phospho-Paxillin Y118 (2541, Cell Signalling), Paxillin (610051, BD transduction laboratories), Zyxin (307011, SYSY), FAK (C-20, sc-558, Santa Cruz), Vinculin (ab18058, Abcam), VASP (610447, BD transduction laboratories), Parvin (4026, Cell Signalling Technology), CrkII (SAB4500470, Sigma) and CrkL (sc-365092, Santa Cruz) or anti-KSHV TK (K1-A12)(mAb, Stevenson lab).

Primary antibodies were detected with either Alexa Fluro 568 goat anti-rabbit or Alexa Fluro 568 donkey anti-mouse (Invitrogen). Actin was stained with Alexa568-conjugated Phalloidin (Invitrogen). MuHV-4 proteins were stained using mAbs 3F7 (glycoprotein, gN) (May et al, 2005), MG-12B8 (capsid, ORF65) (Gillet et al, 2006), PG-8A7 (Large subunit of RNR, ORF61)(Gill et al, 2010) and BN-6C12 (Tegument component, ORF75c) (Gaspar et al, 2008). Stained cells were mounted in ProLong Gold anti-fade reagent with DAPI (Invitrogen). For time-lapse imaging, live cells grown on iwaki glass based dishes (VWR) housed in a heated incubation chamber with constant CO₂. All images and contraction movies were captured using either a Leica SP2 Confocal microscope.
Viruses

ORF21 flanking sequences were amplified by PCR to incorporated required restriction sites, LHS flank coordinate positions 31441-32879 and RHS flank 34054-35931 (based on genome sequence AF105037). The LHS flank was cloned into pSP73 using incorporated BglII and EcoRI restriction sites, generating pSP73-LHSfl. The GFP-KSHV-TK (WT or Y3F mutant) cassette from pEGFPC2-KSHV TK was digested with Eco47III and SalI and cloned into pSP73-LHSfl. The RHS flank was cloned into the resultant pSP73-LHSfl.-GFP-KSHV-TK plasmid, generating pSP73-LHSfl.-GFP-KSHV-TK-RHSfl. Flanked GFP-KSHV-TK was amplified and sub-cloned blunt into pST76-SR shuttle vector. The GFP-KSHV-TK coding sequence was then recombined into MuHV-4 BAC ORF21 locus by standard protocols (Adler et al, 2000). The MHV-68 BAC (MuHV-4 [g-KSHV-TK] was reconstituted into infectious virus by transfection into BHK-21 cells using TransIT-LT1 (Mirus). The loxP-flanked BAC cassette was removed by passaging the virus through 3T3-CRE cells. All virus stocks were grown in BHK-21 cells. Cell debris was pelleted by low-speed centrifugation (1,000xg, 3 mins) and virions were recovered from the supernatants by high-speed centrifugation (38,000xg, 90 mins), and stored at -70°C. Viruses were titered by plaque assay on BHK-21 cells (de Lima et al, 2004). rKSHV.219/Vero cells (a generous gift from Professor J. Vieira, and kindly supplied by Professor D. Blackbourn) (Vieira & O’Hearn, 2004), were lytically activated using 3mM sodium butyrate. Y-27632 (20µM) was added 10h after induction and maintained through-out the experiment. KSHV-lyt virus, a generous gift of Professor W. Brune, was propagated in hTERT-RPE1 cells as previously described (Budt et al, 2011). Filtered virus supernatants were to infect HeLa cells for 30h in the presence or absence of 20µM Y-27632.
**Immunoprecipitation and immunoblotting**

Transfected or infected cells were lysed (20 min, 4°C) in 10mM Tris, pH 7.6, 150mM NaCl, 5mM EDTA, 10% Glycerol, 1% Triton X100, 1 mM phenylmethylsulfonyl fluoride, 1mM Na<sub>3</sub>V<sub>04</sub>, 1mM NaF, plus Complete protease inhibitors (Roche Diagnostics). Insoluble debris was removed by centrifugation (13,000 x g, 15 min/4°C). For immunoprecipitation studies 1μg of antibody specific to FAK (C-20) (sc-558, Santa Cruz), CrkII (610035, BD Transduction laboratories), CrkL (B-1, sc-365092, Santa Cruz), the p85 subunit of PI3-kinase (06-195, Millipore), GFP (ab290, Abcam) or mCherry (M11217, Invitrogen) were incubated with pre-cleared cell lysates o/n at 4°C with constant rotation, followed by incubation with Protein A/G UltraLink Resin (ThermoScientific) 2 h at 4°C with rotation. The resin was pelleted and washed 5x in cell lysis buffer minus SDS and Sodium deoxycholate, and further washed using 50mM Hepes, pH7.4, 150 mM NaCl, 1% Triton X100, 10% Glycerol and precipitated proteins eluted by heating (95°C, 5 min) in Laemmli’s buffer, resolved by SDS-PAGE, and transferred to PVDF membranes. The membranes were then probed for either FAK (C20 antibody), CrkII, CrkIIY221 (34915S, Cell Signalling), CrkL, CrkLY207 (3181S, Cell Signalling), PI3K-p85, mCherry or GFP (mAb JL-8, Clontech), Src (mAb GD11, Millipore) or Paxillin (610051, BD transduction laboratories). For siRNA depletion studies the Actin mAb AC-40 (Sigma) was also used. Primary antibodies were detected using either polyclonal rabbit anti-Mouse (Dako), or horseradish peroxidase-conjugated- anti-rabbit Ig (GE Healthcare UK), followed by enhanced chemiluminescence substrate development (APBiotech). Phospho-Tyrosine was detected using PY99 and MuHV-4 TK with mAb CS1-4A5 (May et al, 2008).

**Expression and Purification of GST-fusion proteins, and in vitro kinase assays.**
BL21 (DE3) Rosetta cells containing pGEX4T1-EBV-TK, MuHV-4-TK, KSHV-TK, KSHV-TK-DEAD or pOPHT-CrkII (His tagged) were grown overnight at 37°C. The next day the bacterial culture was split 1: 10, grown initially for 90min. Expression was induced by the addition of 0.4 mM IPTG for 3 h at 37°C. The bacteria were resuspended in lysis buffer (150 mM NaCl, 50 mM Tris, pH 7.4, 1% Triton X-100, plus PMSF and Protease inhibitors), incubated on ice for 2 h and sonicated. The lysates were clarified by centrifugation and incubated with either glutathione sepharose (for GST-TK preparations) or Ni-NTA Agarose (for His-CrkII) for 1 h at 4°C with rotation. The beads were washed four times in lysis buffer and fusion proteins eluted using 100 mM glutathione (for GST fusions) or 250 imidazole (for His-CrkII) in 50 mM Tris, pH 8.8, 200 mM NaCl. The eluted fusion protein were dialysed overnight against 1X PBS and stored at –70°C until required. Dephosphorylation assay: GST fusion proteins were incubated with reaction buffer (25mM HEPES, pH 7, 50mM Nacl, 2.5mM EDTA, 2.5mM DTT) plus PTP1B (539735, Calbiochem) and incubated at 30°C for 30 m. Samples were extensively washed post incubation if used in subsequent kinase reactions. Kinase assay: GST fusion proteins were incubated with kinase reaction buffer (10 mM HEPES, pH 7.7, 75 mM NaCl, 5 mM MgCl$_2$, 0.5 mM DTT and incubated at 30°C for 30 m. The reactions were stopped by the addition of 2X laemmli sample buffer and analysed by western blotting.

**Mass spectrometry**

Partially purified GST-KSHV-TK was run on a coomassie gel, tryptic digested and the fractionated peptides were analysed by LC-MS/MS to map phosphorylated peptides. MS/MS analysis was completed by Cambridge Centre for Proteomics Core Services (http://www.bioc.cam.ac.uk/uto/deery.html). The identity of each peptide and
phosphorylation sites was determined using Mascot as well as manual interpretation of the spectra.

**Statistical Analysis**

Data are presented as mean ± standard error of the mean and were analyzed by Student’s t test using Prism 6.0 (GraphPad Software, CA). A p value of <0.05 was considered statistically significant.

**Acknowledgments**

This work was supported by Medical Research Council grant G0701185 to PGS and MBG. M.W is supported by Cancer Research UK. We would like to thank Erik Sahai (London Research Institute, Cancer Research UK) and Margaret Frame (Institute of Genetics and Molecular Medicine, University of Edinburgh) for insights and constructive comments. We would also like to thank Susanna Colaco and Janet May for excellent technical support.

Author contribution: MBG designed and performed most of the experiments, and contributed to manuscript writing. RT assisted in experiments. PGS provided funding and resources. MW assisted with experiment design and wrote the manuscript.

Conflict of Interest: None

Supplementary information is available at The EMBO Journal Online
Figure legends

Figure 1. KSHV-TK induces cell contraction and blebbing.

A. Live cell imaging reveals that expression of GFP-KSHV-TK but not GFP induces contraction of HeLa cells (See Movies 1 and 2). The time from the start of imaging is indicated above each panel and the scale bars = 18 µm. Quantification of GFP-KSHV-TK induced cell contraction. The graphs show cell area (µm²) of cells expressing the indicated protein and error bars represent SEM from 3 independent experiments in which n = 224 for GFP and n = 203 for GFP-KSHV-TK. *** indicates P < 0.001. B. Phase images taken from Movie 3 illustrating GFP-KSHV-TK induced blebbing of contracted cells. The time from the start of imaging is indicated above each panel and the scale bars = 18 µm. C. Scanning electron micrographs of HeLa cells expressing GFP or GFP-KSHV-TK. D. Immunofluorescence images illustrating the association of GFP-KSHV-TK, but not GFP, with actin stress fibres. Scale bars = 10 µm.

Figure 2. KSHV-TK induces disruption of the integrity of focal adhesions.

A. Co-expression of GFP-RhoN19 but not GFP inhibits RFP-KSHV TK induced cell contraction. Graphs represent cell area (µm²) of KSHV-TK, RhoN19 or KSHV-TK and RhoN19 expressing cells. Error bars represent SEM from 3 independent experiments, n= 204 for KSHV-TK, n= 223 for RhoN19 and n=189 for KSHV-TK and RhoN19. B. GFP-KSHV-TK induced cell contraction does not occur in cells treated with the ROCK and Myosin II inhibitors Y-27632 and Blebbistatin respectively. Error bars represent SEM from 3 independent experiments, n= 213 for DMSO, n= 189 for Y-27632 and n= 245. C. Immunoblot analysis of Rhotekin pulldown (P.D.) assays reveals that GFP-KSHV-TK increases the level of GTP-bound RhoA (GTP-RhoA). Actin is included as a loading
control and the input lysates are indicated. D. GFP-KSHV-TK but not GFP induces the loss of phospho-tyrosine, phospho-FAK Y925 and phospho-Paxillin Y31 epitopes from focal adhesions. All scale bars represent 20 µm and *** indicates P < 0.001.

Figure 3. Viral expressed KSHV-TK induces cell contraction and loss of focal adhesions.
A. A schematic illustrating the BAC strategy used to generate a recombinant MuHV-4 virus (MuHV-4 [g-KSHV-TK]) in which the endogenous MuHV-4 TK is exchanged for GFP-KSHV-TK. B. Immunoblot analysis of BHK cells infected with MuHV-4, MuHV-4 [g-KSHV-TK], or uninfected using antibodies against phospho-tyrosine (p-Tyr), GFP, MuHV-4 TK, ORF17 (capsid) and glycoprotein N. C. Immunofluorescence analysis of MuHV-4 and MuHV-4 [g-KSHV TK] infected cells with the indicated antibodies reveals GFP-KSHV-TK expressed in the context of lytic infection (MuHV-4 [g-KSHV-TK]) induces the loss of phospho FAK Y925 and Paxillin Y31 from focal adhesions. White arrowheads indicate examples of infected cells expressing GFP-KSHV-TK or GFP (indicating WT MuHV-4 infection, BAC+ virus). D. Immunofluorescence analysis reveals that GFP-KSHV-TK expressed in the context of lytic infection (MuHV-4 [g-KSHV TK]) does not alter focal adhesion integrity (Paxillin) in the presence of the ROCK inhibitor, Y-27632. E. Immunofluorescence analysis of Paxillin in the lytically induced rKSHV.219/Vero cell line in the presence of absence of Y-27632. All scale bars = 20 µm.

Figure 4. The kinase activity of KSHV-TK is required to disrupt focal adhesions
A. Cellular localisation and Immunoblot analysis of phospho-tyrosine (upper panel) and GFP (lower panel) in cells expressing wild type or kinase Dead GFP-KSHV-TK. B. Scanning electron micrographs of HeLa cells expressing GFP or GFP-KSHV-TK-DEAD. C. Immunofluorescence analysis of HeLa cells expressing GFP-KSHV-TK-DEAD (white
arrow heads) with the indicated phospho antibodies. D. Immunofluorescence images of the localization of FAK and Zyxin in HeLa cells expressing GFP-KSHV-TK-DEAD (white arrow heads). E. Purified recombinant GST-EBV-TK, GST-MuHV-4 and GST-KSHV-TK immunoblotted for phosphotyrosine and GST following a sequential dephosphorylation and kinase reaction. F. Purified recombinant GST-KSHV-TK and GST-KSHV-TK-KINASE-DEAD immunoblotted for phosphotyrosine and GST. G. Immunoblot analysis demonstrating that the N-terminus of KSHV-TK is only auto-phosphorylated by the kinase domain in cis. All scale bars = 20 µm.

**Figure 5. The activity of KSHV-TK depends on tyrosine 65 and 85 phosphorylation**

A. Immunoblot analysis of N-terminal deletions of KSHV-TK demonstrates that the first 100 amino acids are required for tyrosine phosphorylation. B. Immunoblot analysis reveals that mutation of tyrosine 65, 85 and 120 ablates tyrosine phosphorylation of the KSHV-TK. C-E. Immunofluorescence analysis with the indicated antibodies reveals that mutation of tyrosines 65, 85 and 120 to phenylalanine abrogates the ability of GFP-KSHV-TK to induce loss of phospho-tyrosine epitopes, phospho-Paxillin and phospho-FAK from focal adhesions. F. Immunoblot analysis of level of GTP-bound and total RhoA in cells expressing the indicated GFP-tagged KSHV-TK proteins. G. Immunofluorescence analysis reveals that localization of paxillin at focal adhesions is unaffected by KSHV-TK-Y3F expressed in the context of lytic infection. Scale bars = 20 µm.

**Figure 6. The disruptive activity of KSHV-TK is dependent on FAK and Paxillin**

A. Immunoblot analysis reveals that GFP-KSHV-TK WT, Y2F and Y3F but not GFP-KSHV-TK-DEAD associates with FAK. B. GFP-KSHV-TK does not displace Paxillin or Zyxin from focal adhesions (white arrow heads) or induce contraction in the absence of
FAK. C. GFP-KSHV-TK does not induce loss zyxin and p-Tyr from focal adhesions or contraction of HeLa cells depleted of paxillin. Error bars represent SEM from 3 independent experiments, n= 196 for mock siRNA and n= 229 for paxillin siRNA and *** indicates P < 0.001. Scale bars = 20 µm.

Figure 7. Phosphorylated tyrosine 65/85 interact with Crk family members

A. A schematic representation of the Crk SH2 consensus binding motifs in KSHV-TK. B. Immunoblot analysis of GFP antibody immunoprecipitates reveals that GFP-KSHV-TK but not Y2F or GFP associates with CrkI, II and L. C. Immunofluorescence analysis reveals CrkII associates with GFP-KSHV-TK but not the Y2F mutant. D. Immunoblot analysis of RFP antibody immunoprecipitates reveals that RFP-KSHV-TK specifically associates with the SH2 domain of CrkII and CrkL. E. Immunofluorescence analysis of phosphotyrosine epitopes in cells expressing GFP-CrkII SH2, GFP-CrkL SH2, RFP-KSHV-TK or a combination of CrkII/LSH2 and RFP-KSHV-TK. Arrow heads represent contracted KSHV-TK expressing cells. The SH2 domains of CrkII or L block KSHV-TK induced cell rounding. Scale bars = 20 µm.

Figure 8. KSHV-TK associates with the p85 regulatory subunit of PI3-kinase.

A. A schematic representation of the p85 regulatory subunit SH2 consensus-binding motif of PI3-Kinase in KSHV-TK. B. Immunoblot analysis reveals that GFP-KSHV-TK WT and Y2F but not Y120F associates with p85 of PI3-Kinase. C. Immunoblot analysis of p85 PI3-Kinase antibody immunoprecipitates reveals that GFP-KSHV-TK and its Y2F mutant but not Y120F associates with p85 of PI3-Kinase. D. Immunoblot analysis of CrkII and CrkL antibody immunoprecipitates reveals that GFP-KSHV-TK and the p85 PI3-Kinase associate with CrkII and CrkL. No association is observed with the Y2F, Y3F or KINASE-DEAD TK. E. Tyrosine phosphorylation of CrkII and CrkL is only up
regulated in cells expressing GFP-KSHV-TK. F. Immunoblot analysis reveals that recombinant His-CrkII binds to and is phosphorylated by KSHV-TK but not the Y2F or Y3F mutants.

Supplementary Figures

Figure S1
A. Immunofluorescence images showing the localization of GFP and GFP-KSHV-TK in COS and BHK cells. B. GFP-HSV1-TK does not induce cell contraction or loss of phospho-tyrosine and phospho-paxillin Y31 epitopes from focal adhesions. C. Transmission electron micrographs of HeLa cells expressing GFP or GFP-KSHV-TK. D. Treatment of HeLa cells with the cell-permeable caspase inhibitor, Z-VAD-FMK does not inhibit GFP-KSHV-TK induced cell contraction. E. GFP-KSHV-TK but not GFP induces the formation of actin stress fibres and cell rounding. Quantification of GFP-KSHV-TK induced cell contraction. The graph shows the percentage of cells with flattened morphology (Flat), flattened morphology with central actin stress fibers (Flat + SF), and rounded morphology calculated from 3 independent experiments in which n= 215 for GFP and n= 218 for GFP-KSHV-TK. Scale bars = 20 µm.

Figure S2
A. Immunofluorescence images showing that Y-27632 and Blebbistatin treatment does not induce cell contraction or loss of phosphotyrosine, phospho-FAK-Y397, Y925 and phospho-paxillin-Y31 epitopes from focal adhesions. B. GFP-KSHV-TK but not GFP leads to a loss of the phospho-FAK Y397/Y861 and phospho-Paxillin Y118 signals at focal adhesions. C. The graphs represent the total cell fluorescence when staining for phospho-Paxillin Y31 or phospho-FAKY925 in cells expressing GFP or GFP-KSHV-TK. Only transfected cells were quantified. The error bars represent SEM from 3
independent experiments in which n= 123 for GFP and n= 126 for GFP-KSHV-TK when staining for phospho-Paxillin Y31 and phospho-FAKY925. Immunoblot analysis showing that GFP-KSHV-TK but not GFP leads to reduced Paxillin-Y31 and FAK-Y925 phosphorylation. Scale bars = 20 μm.

**Figure S3**

A. GFP-KSHV-TK induces the loss of FAK, Paxillin and Zyxin from focal adhesions. White arrowheads indicate cells expressing GFP-KSHV-TK. B. Expression of GFP-KSHV-TK but not GFP leads to a loss of Parvin, VASP and Vinculin from focal adhesions. C. Expression of untagged KSHV-TK or RFP-KSHV-TK induces the loss of GFP-FAK from focal adhesions. Scale bars = 20 μm.

**Figure S4**

A. HeLa cells infected with MuHV-4 or MuHV-4 [g-KSHV-TK] labelled with the indicated antibodies reveals that both viruses express early and late lytic proteins. B. Immunofluorescence analysis of phosphotyrosine staining in HeLa cells infected with KSHV-lyt in the presence of absence of Y-27632. Scale bars= 20 μm.

**Figure S5**

GFP-KSHV-TK-DEAD does not induce loss of paxillin, phospho-paxillin (Y118), Parvin, VASP or Vinculin from focal adhesions. Scale bars = 20 μm.

**Figure S6**

A. Immunoblot analysis of Y to F mutants demonstrates that Y65 and Y85 of KSHV are phosphorylated. B. Immununofluorescence images showing that the Y2F mutant does not
induce cell contraction or loss of phosphotyrosine epitopes from focal adhesions. C. Immununofluoresence images showing that the Y2F mutant does not induce loss of phospho-Paxillin Y31 or phospho-FAK Y925 epitopes from focal adhesions. D. Expression of GFP-KSHV-TK but not GFP induces contraction of zyxin labelled FAK+/+ cells. Scale bars = 20 μm.

Figure S7
Partially purified GST-KSHV-TK fractionated and analysed by LC-MS/MS to map phosphorylated peptides. KSHV-TK showing auto-phosphorylation of tyrosine residues 65, 85 and 120. The identity of each peptide and phosphorylation sites is shown in the manual interpretation of the spectra.

Supplementary Movies

**Movie S1.** The movie shows GFP-KSHV-TK (top panel) induced contraction of a HeLa cell in phase contrast (bottom panel) over a period of 2140s. The movie starts 16 hours after the cell was first transfected with GFP-KSHV-TK.

**Movie S2.** The movie shows that GFP (top panel) does not induce contraction of HeLa cells in phase contrast (bottom panel) over a 1138s. The movie starts 16 hours after the cells were first transfected with GFP.

**Movie S3.** A phase contrast movie of a HeLa cell undergoing GFP-KSHV-TK induced contraction and blebbing over a period of 620s. The movie starts 18 hours after the cells were first transfected with GFP-KSHV-TK.
References


Chen MS, Summers WP, Walker J, Summers WC, Prusoff WH (1979) Characterization of pyrimidine deoxyribonucleoside kinase (thymidine kinase) and thymidylate kinase as a multifunctional enzyme in cells transformed by herpes simplex virus type 1 and in cells infected with mutant strains of herpes simplex virus. J Virol 30: 942-945


Gustafson EA, Chillemi AC, Sage DR, Fingeroth JD (1998) The Epstein-Barr virus thymidine kinase does not phosphorylate ganciclovir or acyclovir and demonstrates a narrow substrate specificity compared to the herpes simplex virus type 1 thymidine kinase. Antimicrob Agents Chemother 42: 2923-2931


Gill et al., 2014 KSHV-TK


Figure 1_Gill et al., 2014

A

<table>
<thead>
<tr>
<th></th>
<th>GFP</th>
<th>GFP-KSHV-TK</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 s</td>
<td><img src="image1" alt="Image" /></td>
<td><img src="image2" alt="Image" /></td>
</tr>
<tr>
<td>1138 s</td>
<td><img src="image3" alt="Image" /></td>
<td><img src="image4" alt="Image" /></td>
</tr>
<tr>
<td>0 s</td>
<td><img src="image5" alt="Image" /></td>
<td><img src="image6" alt="Image" /></td>
</tr>
<tr>
<td>1016 s</td>
<td><img src="image7" alt="Image" /></td>
<td><img src="image8" alt="Image" /></td>
</tr>
<tr>
<td>1698 s</td>
<td><img src="image9" alt="Image" /></td>
<td><img src="image10" alt="Image" /></td>
</tr>
</tbody>
</table>

B

<table>
<thead>
<tr>
<th></th>
<th>GFP</th>
<th>GFP-KSHV-TK</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 s</td>
<td><img src="image11" alt="Image" /></td>
<td><img src="image12" alt="Image" /></td>
</tr>
<tr>
<td>386 s</td>
<td><img src="image13" alt="Image" /></td>
<td><img src="image14" alt="Image" /></td>
</tr>
<tr>
<td>444 s</td>
<td><img src="image15" alt="Image" /></td>
<td><img src="image16" alt="Image" /></td>
</tr>
<tr>
<td>620 s</td>
<td><img src="image17" alt="Image" /></td>
<td><img src="image18" alt="Image" /></td>
</tr>
</tbody>
</table>

C

GFP          | GFP-KSHV-TK   |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image19" alt="Image" /></td>
<td><img src="image20" alt="Image" /></td>
</tr>
</tbody>
</table>

D

GFP-KSHV-TK: Actin Merge

GFP          | GFP-KSHV-TK   |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image21" alt="Image" /></td>
<td><img src="image22" alt="Image" /></td>
</tr>
</tbody>
</table>

Actin

GFP          | GFP-KSHV-TK   |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image23" alt="Image" /></td>
<td><img src="image24" alt="Image" /></td>
</tr>
</tbody>
</table>

Bar scale
Figure 3_Gill et al., 2014

A

MuHV-4

ORF20

ORF21(TK)

ORF22 (gH)

MuHV4 (g-KSHV-TK)

B

MuHV4-TK

ORF17 (Capsid)

gN (glycoprotein)

C

MuHV-4 inf.

GFP

MuHV-4-[g-KSHV-TK] inf.

GFP-KSHV-TK

Phospho-Paxillin

Phospho-FAKY925

D

Mock

GFP-KSHV-TK

Paxillin

GFP-KSHV-TK

Paxillin + Y-27632

MuHV-4-[g-KSHV-TK]

E

GFP (BAC+ virus)

RFP (Lytic)

Paxillin

No drug

rKSHV219Vero- Induced

rKSHV219Vero- Induced + Y-27632

Figure 3_Gill et al., 2014
Figure 4_Gill et al., 2014

A

KSHV-TK

KSHV-TK-DEAD

GFP

p-Tyr

GFP-KSHV-TK

B

Mock

KSHV-TK-DEAD

C

KSHV-TK-DEAD Phosphoprotein

phosphotyrosine

FAK Y925

Paxillin Y31

FA protein

D

FAK

Zyxin

E

EBV-TK

MuHV-4-TK

KSHV-TK

MuHV-4-TK

KSHV-TK

MuHV-4-TK

p-Tyr

GST

Input gst-TK

Dephosphorylation (Tyrosine kinase reaction)

GFP-KSHV-TK

GST-KSHV-TK

F

- WT

KINASE-DEAD

p-Tyr

GST

GST-KSHV-TK

G

GFP-KSHV-TK domains

WT KINASE-DEAD CT NT + WT NT

p-Tyr

GFP
Figure 5_Gill et al., 2014
Figure 6_Gill et al., 2014

A

B

C

siRNA Control         GFP-KSHV-TK

Paxillin

Zyxin

phosphotyrosine

siRNA Paxillin         GFP-KSHV-TK

Mock siRNA           Control

Paxillin

Actin

Cell area (\(\mu\text{m}^2\))
Figure 7_Gill et al., 2014

A

Crk SH2 binding motif: p-Y-X-X-P
KSHV-TK-Y65: p-Y-D-V-P

<table>
<thead>
<tr>
<th>N-terminus</th>
<th>C-terminus/Kinase domain</th>
</tr>
</thead>
<tbody>
<tr>
<td>Y(65)</td>
<td>Y(85)</td>
</tr>
<tr>
<td>Y(120)</td>
<td></td>
</tr>
</tbody>
</table>

B

[Images of Western blotting results showing CRKI, CRKII, CRKL, GFP, and input.]

C

[Images of fluorescence microscopy showing CrkII and GFP-KSHV-TK-WT, CrkII and GFP-KSHV-TK-Y2F.]

D

GFP-CrkL-domains

GFP-CrkII-domains

E

[Images showing co-expression of GFP-CrkII SH2, GFP-CrkL SH2, RFP-KSHV-TK, co-expression, and phosphotyrosine localization.]
Figure 8. Gill et al., 2014

A. Y(65) Y(85) Y(120)

<table>
<thead>
<tr>
<th>N-terminus</th>
<th>C-terminus/Kinase domain</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>231</td>
</tr>
</tbody>
</table>

PI3-Kinase, p85 SH2 binding motif: p-Y-X-X-M

KSHV-TK-Y120: p-Y-A-P-M

B. GFP-KSHV-TK

<table>
<thead>
<tr>
<th>WT</th>
<th>Y3F</th>
<th>Y2F</th>
</tr>
</thead>
<tbody>
<tr>
<td>PI3K, p85</td>
<td>GFP</td>
<td>PI3K, p85</td>
</tr>
</tbody>
</table>

Input

C. GFP-KSHV-TK

<table>
<thead>
<tr>
<th>WT</th>
<th>Y3F</th>
<th>Y2F</th>
</tr>
</thead>
<tbody>
<tr>
<td>IP: pI3K, p85</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IP: CrkL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IP: CrkII</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Input</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

D. GFP-KSHV-TK

<table>
<thead>
<tr>
<th>KD</th>
<th>WT</th>
<th>Y3F</th>
<th>Y2F</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bound (IP CrkII)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bound (IP CrkL)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Input</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

E. GFP-KSHV-TK

<table>
<thead>
<tr>
<th>Y21</th>
<th>Y2F</th>
</tr>
</thead>
<tbody>
<tr>
<td>Input</td>
<td></td>
</tr>
<tr>
<td>p-CRkII</td>
<td></td>
</tr>
<tr>
<td>p-CRKl</td>
<td></td>
</tr>
</tbody>
</table>

F. GFP-KSHV-TK

<table>
<thead>
<tr>
<th>Y207</th>
<th>Y3F</th>
<th>Mock</th>
</tr>
</thead>
<tbody>
<tr>
<td>Input</td>
<td></td>
<td></td>
</tr>
<tr>
<td>p-Tyr</td>
<td></td>
<td></td>
</tr>
<tr>
<td>p-Tyr</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GFP</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figure 8_Gill et al., 2014
Figure S2  Gill et al., 2014

A

Paxillin Y31  FAK-Y925  FAK-Y397  phosphotyrosine

Mock

Y-27632 Blebbistatin

B

GFP  Phosphoprotein  GFP-KSHV-TK  Phosphoprotein

FAK Y397

FAK Y861

Paxillin Y118

C

Total cell fluorescence

GFP  GFP-KSHV-TK

GFP  GFP-KSHV-TK
Figure S3 Gill et al., 2014
Figure S4_Gill et al., 2014

A

MuHV-4-[g-KSHV-TK]  MuHV-4

ORF61

ORF65

ORF75c

gN

B

GFP (BAC+)  phosphotyrosine

No Drug

Y-27632
**A**

Expression of GFP-KSHV-TK mutant in different cell lines: Y65F, Y85F, Y2F, Mock, KSHV-TK. The blot shows the expression levels of p-Tyr and GFP.

**B**

Immunofluorescence images of cells expressing different mutants: KSHV-TK, Y65F, Y85F, Y2F. The images show the distribution of Phosphotyrosine (arrowheads).

**C**

Immunofluorescence images of cells expressing Phospho-Paxillin Y31 and Phospho-FAKY925 mutants. The images show the localization of these phosphorylation sites in Y2F cells.

**D**

Immunofluorescence images of cells expressing GFP, Zyxin, GFP-KSHV-TK, and Zyxin. The images show the expression and localization of these proteins.
(Phospho-Tyrosine aa 120)
Peptide Sequence: (aa 110)-LSATDDDSGDpYAPMDR-(aa 125)

<table>
<thead>
<tr>
<th>β, ions</th>
<th>L</th>
<th>S</th>
<th>A</th>
<th>T</th>
<th>D</th>
<th>D</th>
<th>D</th>
<th>S</th>
<th>G</th>
<th>D</th>
<th>Y</th>
<th>A</th>
<th>P</th>
<th>M</th>
<th>D</th>
<th>R</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1711.57</td>
<td>1624.54</td>
<td>1553.50</td>
<td>1452.46</td>
<td>1337.43</td>
<td>1222.40</td>
<td>1107.38</td>
<td>1020.34</td>
<td>963.32</td>
<td>848.30</td>
<td>605.27</td>
<td>534.23</td>
<td>437.18</td>
<td>290.14</td>
<td>175.11</td>
<td></td>
</tr>
</tbody>
</table>

(Phosphotyrosine aa 85)
Peptide Sequence: (aa 61)-TSYIYDVPTVPTSKPWHLMHDNSLpYATPR-(aa 89) (29mer)

<table>
<thead>
<tr>
<th>β, ions</th>
<th>L</th>
<th>S</th>
<th>Y</th>
<th>D</th>
<th>V</th>
<th>P</th>
<th>T</th>
<th>V</th>
<th>P</th>
<th>T</th>
<th>S</th>
<th>K</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1917.84</td>
<td>1802.79</td>
<td>1634.71</td>
<td>1497.65</td>
<td>1384.57</td>
<td>1263.53</td>
<td>1116.47</td>
<td>1001.44</td>
<td>887.40</td>
<td>800.37</td>
<td>687.28</td>
<td>444.26</td>
<td>373.21</td>
</tr>
</tbody>
</table>

(Phosphotyrosine aa 65)
Peptide Sequence: (aa 61)-TSYpYDVPTVPTSKPWHLMHDNSLYATPR-(aa 89) (29mer)

<table>
<thead>
<tr>
<th>β, ions</th>
<th>L</th>
<th>S</th>
<th>Y</th>
<th>D</th>
<th>V</th>
<th>P</th>
<th>T</th>
<th>V</th>
<th>P</th>
<th>T</th>
<th>S</th>
<th>L</th>
<th>Y</th>
<th>A</th>
<th>T</th>
<th>P</th>
<th>R</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1740.82</td>
<td>1554.74</td>
<td>1417.68</td>
<td>1304.60</td>
<td>1173.56</td>
<td>1036.50</td>
<td>921.47</td>
<td>807.43</td>
<td>720.40</td>
<td>607.31</td>
<td>444.25</td>
<td>373.21</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Fig. S7_Gill et al., 2014
**Uncropped Figure 6C**

- Paxillin
- Actin

**Uncropped Figure 7B**

- Input samples
- Bound samples
- CrkII
- CrkI
- CrkL

(GFP bound and IP as shown in original figure)

**Uncropped Figure 7D**

- Input samples
- Bound samples
- HC
- GFP
- LC
- GFP
- RFP
- HC
- LC
- GFP
- RFP

LHS panel

RHS panel
Uncropped Figure 8E

- p-CrkIIY221
- CRKII
- p-CRKL207
- CRKL

Uncropped Figure 8F

- p-Tyr for IP GFP
- p-Tyr for His-CrkII
- CrkII
- GFP